Brokerages Set DRI Healthcare Trust (TSE:DHT.UN) PT at C$17.94

DRI Healthcare Trust (TSE:DHT.UN) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is C$17.94.

A number of equities analysts have issued reports on DHT.UN shares. Raymond James lowered their target price on DRI Healthcare Trust from C$23.00 to C$22.00 in a report on Wednesday, November 13th. CIBC lowered their target price on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating for the company in a report on Thursday, December 12th. Finally, Scotiabank upped their target price on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th.

DRI Healthcare Trust Stock Performance

Shares of DHT.UN stock opened at C$12.25 on Friday. DRI Healthcare Trust has a twelve month low of C$10.39 and a twelve month high of C$17.43. The business has a fifty day simple moving average of C$12.26 and a 200 day simple moving average of C$12.57.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.